Dr. Monk on Bevacizumab in Cervical Cancer

Bradley Monk, MD
Published Online: Tuesday, December 31, 2013
Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the role of bevacizumab in the treatment of metastatic cervical cancer.

Monk says the recently completed phase III GOG 240 study looked at the addition of bevacizumab to standard chemotherapy for the treatment of metastatic cervical cancer. The study showed that adding bevacizumab improved overall survival by nearly 4 months and improved response rate to about 50%.

Monk says this is a remarkable achievement, since metastatic cervical cancer is resistant to chemotherapy.

Online CME Activities
Free CME from PER
Advances in Multiple Myeloma
Cancer Summaries and Commentaries™: Update from Chicago: Castrate Resistant Prostate Cancer and Advanced Melanoma
Community Practice Connections™: Novel Perspectives in Personalizing EGFR-Targeted Therapy in NSCLC: Frontline and Overcoming Resistance
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Gynecologic Cancers
More Reading
$auto_registration$